Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial

NCT05571917 · View on ClinicalTrials.gov ↗

Study Summary

This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment. The investigators hypothesize that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to Enhanced Usual Care and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.

Interventions

  • BEHAVIORAL Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)
  • BEHAVIORAL Enhance Usual Care (EUC)

Study Locations (2)

Michigan

  • University of Michigan — Ann Arbor

New Mexico

  • University of New Mexico — Albuquerque

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2023-05-05
Est. Completion 2026-12-31
Phase NA

Sponsor

University of New Mexi

107 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05571917

The ClinicalTrials.gov registry entry for NCT05571917 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexi, which has 107 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions — of which Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05571917 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Michigan, New Mexico. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05571917 about?

NCT05571917 is a clinical study titled "Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial". This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are...

What is the current status of trial NCT05571917?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2023-05-05. Estimated completion is 2026-12-31.

What conditions does trial NCT05571917 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05571917?

The interventions under investigation include: Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) (BEHAVIORAL), Enhance Usual Care (EUC) (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05571917?

This trial is sponsored by University of New Mexi, which has 107 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05571917 being conducted?

This trial has 2 study locations across Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial